Mpox

Mpox is an exotic infectious disease caused by the Mpox virus. The disease was first identified in laboratory monkeys, thus earning its name, but in its natural state, it seems to infect rodents more than primates. A fever, headache, muscle pains, swollen lymph nodes, and fatigue are the first symptoms in humans. After this, a rash forms with blisters and crusts. Symptoms typically appear 7 to 14 days after exposure. In most cases, symptoms last 2 to 4 weeks. Children, pregnant women, and people with suppressed immune systems are at greater risk of severe cases.

Overview

Feature Articles

Latest Mpox News and Research

Celebrating 25 years of GOARN's global health impact

Celebrating 25 years of GOARN's global health impact

Africa CDC and WHO strengthen mpox response with updated strategy

Africa CDC and WHO strengthen mpox response with updated strategy

Africa faces growing mpox threat amid foreign aid reductions

Africa faces growing mpox threat amid foreign aid reductions

Slashed federal funding cancels vaccine clinics amid measles surge

Slashed federal funding cancels vaccine clinics amid measles surge

Mpox virus poses rising global epidemic and pandemic threat

Mpox virus poses rising global epidemic and pandemic threat

Research highlights rising risk of human-to-human mpox transmission

Research highlights rising risk of human-to-human mpox transmission

Artificial intelligence tool predicts virus outbreak hotspots

Artificial intelligence tool predicts virus outbreak hotspots

Registration Now Open for World Vaccine Congress Washington 2025: Leading Experts from Government, WHO, CEPI, and more to Speak

Registration Now Open for World Vaccine Congress Washington 2025: Leading Experts from Government, WHO, CEPI, and more to Speak

Third International Health Regulations Emergency Committee meeting addresses mpox upsurge

Third International Health Regulations Emergency Committee meeting addresses mpox upsurge

Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial

Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial

WHO Director-General issues revised recommendations on mpox emergency

WHO Director-General issues revised recommendations on mpox emergency

New mpox variant can spread rapidly across borders

New mpox variant can spread rapidly across borders

Study explains why tecovirimat fails against some mpox strains

Study explains why tecovirimat fails against some mpox strains

Surge in violence in eastern Democratic Republic of the Congo leads to healthcare crisis

Surge in violence in eastern Democratic Republic of the Congo leads to healthcare crisis

Penn researchers develop optimized framework for COVID-19 vaccination distribution

Penn researchers develop optimized framework for COVID-19 vaccination distribution

SHEA calls for continued U.S. partnership with the World Health Organization

SHEA calls for continued U.S. partnership with the World Health Organization

Predicting H5N1 disease severity based on T cell responses

Predicting H5N1 disease severity based on T cell responses

New class of antivirals shows promise against multiple viruses

New class of antivirals shows promise against multiple viruses

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

Fossil fuel industry influences medical research, raising ethical concerns

Fossil fuel industry influences medical research, raising ethical concerns

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.